Chronic Ipamorelin Treatment Doesn't Desensitize the GH System in Young Female Rats
Chronic ipamorelin treatment in young female rats maintained GH-releasing effectiveness without desensitizing somatotroph cells, though it modulated GHRH and somatostatin receptor expression.
Quick Facts
What This Study Found
Chronic ipamorelin treatment maintained somatotroph GH-releasing responsiveness without desensitization, though GHRH and somatostatin receptor expression were modulated — adaptive changes that preserved overall drug effectiveness.
Key Numbers
How They Did This
Animal study in young female rats with chronic ipamorelin treatment. Pituitary somatotroph responsiveness tested ex vivo. GHRH receptor and somatostatin receptor expression measured by molecular techniques.
Why This Research Matters
Maintaining effectiveness during chronic use is essential for GH secretagogues to serve as long-term GH replacement therapy. This study provides reassurance that ipamorelin doesn't lose its punch.
The Bigger Picture
Drug tolerance is a major barrier to chronic peptide therapy. Ipamorelin's maintained effectiveness suggests it could work long-term, unlike drugs that lose efficacy through receptor desensitization.
What This Study Doesn't Tell Us
Young female rats; may not predict adult human responses. Receptor expression changes suggest adaptive mechanisms that could eventually affect efficacy with very long-term use.
Questions This Raises
- ?Does ipamorelin maintain effectiveness over years of use in humans?
- ?Do the receptor expression changes eventually limit response?
- ?Is ipamorelin's sustained efficacy unique or shared by other GH secretagogues?
Trust & Context
- Key Stat:
- No desensitization Chronic ipamorelin preserved pituitary GH responsiveness despite receptor expression changes — the drug maintains its effectiveness over time
- Evidence Grade:
- Preliminary animal evidence with functional and molecular characterization of chronic treatment effects on the GH axis.
- Study Age:
- Published in 2002. Ipamorelin's sustained efficacy has been noted in multiple studies, supporting its clinical development for long-term use.
- Original Title:
- Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
- Published In:
- Histology and histopathology, 17(3), 707-14 (2002)
- Authors:
- Jiménez-Reina, L, Cañete, R, de la Torre, M J, Bernal, G
- Database ID:
- RPEP-00737
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does ipamorelin stop working over time?
Not in this study. Chronic ipamorelin treatment maintained its GH-releasing effect without desensitizing the pituitary. This is important because many hormonal drugs lose effectiveness with continued use.
Is this different from other GH peptides?
Some GH secretagogues show reduced effectiveness over time. Ipamorelin's maintained potency may relate to its high selectivity — it activates fewer off-target pathways that could trigger desensitization.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00737APA
Jiménez-Reina, L; Cañete, R; de la Torre, M J; Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.. Histology and histopathology, 17(3), 707-14. https://doi.org/10.14670/HH-17.707
MLA
Jiménez-Reina, L, et al. "Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.." Histology and histopathology, 2002. https://doi.org/10.14670/HH-17.707
RethinkPeptides
RethinkPeptides Research Database. "Influence of chronic treatment with the growth hormone secre..." RPEP-00737. Retrieved from https://rethinkpeptides.com/research/jimenez-reina-2002-influence-of-chronic-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.